Currently, although surgical aortic valve replacement (SAVR) is still the golden standard in treatment of severe aortic stenosis according to the guideline, transcatheter aortic valve implantation (TAVI) is gradually becoming a common treatment for patients who are prohibitive or in high risk for SAVR. Recently, the valve manufacturers, including medical companies in China, are making their utmost to develop valve device, leading remarkable results achieved by TAVI. With the complications being controlled, TAVI displays promising future. It is likely that TAVI is expected to become a substitute for SAVR to treat patients with aortic stenosis or even aortic regurgitation.
目前，尽管严重主动脉狭窄的治疗指南仍以外科手术置换(surgical aortic valve replacement，SAVR)为治疗标准，但随着大血管外科技术的不断发展，经导管主动脉瓣置换术(transcatheter aortic valve implantation，TAVI)逐渐成为高危和禁忌SAVR患者的常规治疗措施。近年来各瓣膜厂商，包括国内医药公司，对瓣膜技术极力地推进，使得TAVI技术取得了显著成效，加上其并发症也得到了有效控制，TAVI有望在治疗主动脉狭窄乃至关闭不全上取代传统术式，应用前景可观。.